Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Patients harboring uncommon EGFR exon 19 deletion-insertion mutations respond well to first-generation EGFR inhibitors and osimeritinib upon acquisition of T790M

Fig. 1

Flow chart of the study design. 3054 treatment-naïve patients with advanced NSCLC performing NGS molecular test in our hospital were successively screened. 41 patients with EGFR 19delins mutation met the inclusion criteria, and then 41 patients with EGFR 19del mutation were enrolled successively at random, receiving first-generation EGFR TKI gefitinib or icotinib or erlotinib as first-line therapy. At progression, the resistance mechanisms were analyzed. And the PFS and response rates after second-line osimertinib were also evaluated

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us